Friday, 20 Oct 2017

You are here

RheumNow Week in Review – 14 October 2015

Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:

  1. Prevalence of noninfectious uveitis in USA: Nearly 300,000 adults and 22,000 children in 2015 (based on claims data). http://buff.ly/2e7ew4y
  2. Global biosimilars sales = 3.5 billion in 2015; poised to reach $15.6 billion by 2022. https://t.co/TATv2rgYTM
  3. Patients with VERY high levels of CRP & nonspecific findings should raise suspicion for other non-rheumatic diagnoses (infection, malignancy). https://t.co/xbCTGXPd5L
  4. Medicare study shows no increased risk of breast cancer in RA or IBD women taking MTX, 6MP or TNF inhibitors! https://t.co/lHyUbyjNCQ
  5. Norwegian HUNT study shows no increased risk of fracture among 2804 self reported psoriasis patients. https://t.co/PHNMUac27A
  6. High ESR/CRP in a Rheumatology Hospital: Rheumatic diseases were most common (52%); lead by PMR (38%), seronegative RA, infection (25%), neoplasia (9%). https://t.co/9mkJhQMXwZd
  7. Diabetes has frequent articular and periarticular findings: including OA knee (most common at 49%), carpal tunnel syndrome (29%), frozen shoulder (23%), cheiroarthropathy (16%). https://t.co/pGRNI6wQTQ
  8. Metanalysis: ankle replacement (TAA) vs arthrodeisis w/ similar outcomes but more reoperations, complications w/ TAA. https://t.co/dGbZLl28mi
  9. Phase II ACCLAIM small trial fails to show significant benefit/safety of Abatacept in multiple sclerosis (42 pts). https://t.co/GeU5XnhePt
  10. Endocannabinoid, Resunab (JBT-101), in a clinical trial for scleroderma. It decreases TGF-B & collagen. https://t.co/Iu8OLPm5BC
  11. Mayo study of incident Sarcoidosis shows 3 fold higher risk of venous thrombosis & 4 fold risk of pulm embolism. https://t.co/C4gZc951aJ
  12. My Take on New Ocular Screening Guidelines for Plaquenil 
  13. 1/3 of First Degree Relatives to AS patients are at Risk of Spondyloarthritis
  14. New Criteria for the Cryopyrinopathies (CAPS)
  15. Long-Term Outcomes of Aromatase Inhibitor Arthralgias
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review - 20 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.